EyePoint (EYPT) Stock Price
EyePoint Price
Revenue has compounded at 17.5% per year over the past 19 years to 31.37 M USD. EyePoint's net margin stands at -739.4%, down from -158.1% several years earlier. Analysts set a median price target of 33.66 USD, implying 656.8% above the current price. Of 18 analysts, 17 rate the stock a buy — an overall Buy consensus. The stock trades about 14% above its 52-week low.
EyePoint stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of EyePoint over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how EyePoint stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing EyePoint's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | EyePoint Price |
|---|---|
| 8/28/2026 | 4.45 USD |
| 8/27/2026 | 4.59 USD |
| 8/26/2026 | 4.99 USD |
| 8/25/2026 | 5.01 USD |
| 8/24/2026 | 5.02 USD |
| 8/21/2026 | 5.32 USD |
| 8/20/2026 | 5.40 USD |
| 8/19/2026 | 6.06 USD |
| 8/18/2026 | 5.22 USD |
| 8/14/2026 | 5.22 USD |
| 8/13/2026 | 4.78 USD |
| 8/12/2026 | 4.79 USD |
| 8/11/2026 | 4.62 USD |
| 8/10/2026 | 4.72 USD |
| 8/7/2026 | 4.92 USD |
| 8/6/2026 | 4.54 USD |
| 8/5/2026 | 4.27 USD |
| 8/4/2026 | 4.27 USD |
| 8/3/2026 | 4.40 USD |
| 7/31/2026 | 4.34 USD |
| 7/30/2026 | 4.56 USD |
| 7/29/2026 | 4.17 USD |
| 7/27/2026 | 4.37 USD |
| 7/23/2026 | 4.42 USD |
| 7/22/2026 | 4.48 USD |
| 7/21/2026 | 4.62 USD |
| 7/20/2026 | 4.48 USD |
| 7/17/2026 | 4.71 USD |
| 7/16/2026 | 4.62 USD |
| 7/15/2026 | 4.91 USD |
EyePoint Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
EyePoint Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.00 | 1.00 | 7.00 | 2.00 | 20.00 | 34.00 | 36.00 | 41.00 | 46.00 | 43.00 | 31.00 | 1.00 | 17.00 | 196.00 | 437.00 | 621.00 |
| 766.67 | -96.15 | 600.00 | -71.43 | 900.00 | 70.00 | 5.88 | 13.89 | 12.20 | -6.52 | -27.91 | -96.77 | 1,600.00 | 1,052.94 | 122.96 | 42.11 |
| 100.00 | 100.00 | 100.00 | -750.00 | 85.00 | 82.35 | 77.78 | 80.49 | 89.13 | 90.70 | 93.55 | 93.55 | 93.55 | 93.55 | 93.55 | 93.55 |
| 26.00 | 1.00 | 7.00 | -15.00 | 17.00 | 28.00 | 28.00 | 33.00 | 41.00 | 39.00 | 29.00 | 0.94 | 15.90 | 183.35 | 408.81 | 580.94 |
| 6.00 | -21.00 | -18.00 | -26.00 | -50.00 | -38.00 | -53.00 | -99.00 | -75.00 | -145.00 | -243.00 | -1.00 | -17.00 | -196.00 | -437.00 | -621.00 |
| 23.08 | -2,100.00 | -257.14 | -1,300.00 | -250.00 | -111.76 | -147.22 | -241.46 | -163.04 | -337.21 | -783.87 | -100.00 | -100.00 | -100.00 | -100.00 | -100.00 |
| 6.00 | -21.00 | -18.00 | -53.00 | -56.00 | -45.00 | -58.00 | -102.00 | -70.00 | -130.00 | -231.00 | -209.00 | -156.00 | -91.00 | 6.00 | 73.00 |
| -146.15 | -450.00 | -14.29 | 194.44 | 5.66 | -19.64 | 28.89 | 75.86 | -31.37 | 85.71 | 77.69 | -9.52 | -25.36 | -41.67 | -106.59 | 1,116.67 |
| 2.94 | 3.42 | 4.45 | 9.49 | 10.67 | 14.50 | 32.70 | 37.35 | 42.17 | 64.56 | 83.03 | 83.03 | 83.03 | 83.03 | 83.03 | 83.03 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales EyePoint generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue EyePoint retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare EyePoint's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares EyePoint has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against EyePoint's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
EyePoint stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
EyePoint Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
EyePoint business model & stock analysis
EyePoint SWOT Analysis
Strengths
EyePoint Pharmaceuticals Inc has a strong portfolio of innovative eye care products.
The company has a robust research and development pipeline with potential for future growth and expansion.
EyePoint Pharmaceuticals Inc has a highly experienced and talented team of scientists and researchers.
The company has established strong relationships with key stakeholders, including healthcare professionals and regulatory authorities.
Weaknesses
EyePoint Pharmaceuticals Inc faces intense competition from other players in the eye care industry.
The company's dependence on a few key products for revenue generation increases its vulnerability to market fluctuations.
EyePoint Pharmaceuticals Inc may face challenges in effectively marketing and promoting its products to target customers.
The company's financial performance has been inconsistent in recent years.
Opportunities
Growing elderly population and increasing prevalence of eye-related diseases present a significant market opportunity for EyePoint Pharmaceuticals Inc.
The company can explore partnerships and collaborations to expand its global reach and enter new markets.
Advancements in technology and drug delivery systems offer opportunities for the development of innovative eye care solutions.
EyePoint Pharmaceuticals Inc can leverage its strong R&D capabilities to develop differentiated products and gain a competitive advantage.
Threats
Stringent regulatory requirements and approval processes pose a threat to the timely launch of new products.
Rapidly changing market dynamics and evolving customer preferences can impact the demand for EyePoint Pharmaceuticals Inc's products.
The company may face legal and intellectual property challenges from competitors.
Fluctuating raw material prices can influence the company's production costs and profit margins.
EyePoint Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
EyePoint Segments
EyePoint Revenue by Segment (1/5)
3 Years
5 Years
Max
Details
EyePoint Revenue by Segment (2/5)
3 Years
5 Years
Max
Details
EyePoint Revenue by Segment (3/5)
3 Years
5 Years
Max
Details
EyePoint Revenue by Segment (4/5)
3 Years
5 Years
Max
Details
EyePoint Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
EyePoint Revenue by Region
3 Years
5 Years
10 Years
Max
Details
EyePoint Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
EyePoint historical P/E ratio, EBIT multiple, and P/S ratio
EyePoint annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
EyePoint shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
EyePoint stock splits
Current EyePoint forecasts and price targets in September 2026
Analyst Price Targets 2026EyePoint Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/18/2026 | Downgrade | OutperformSector Perform | 49 | |
| 8/18/2026 | Downgrade | BuyNeutral | – | |
| 8/18/2026 | Maintained | Buy | 48 | |
| 8/18/2026 | Downgrade | BuyNeutral | – | |
| 8/17/2026 | Downgrade | OverweightNeutral | 59 | |
| 8/17/2026 | Maintained | Buy | 56 | |
| 8/17/2026 | Maintained | Buy | – | |
| 8/7/2026 | Maintained | Buy | – | |
| 8/6/2026 | Maintained | Buy | – | |
| 8/6/2026 | Maintained | Overweight | 41 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
EyePoint Earnings Calls
EyePoint Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | -0.97USD | - | 414,997.00USD | - | 2026 Q2 |
| 5/6/2026 | -0.81USD | - | 359,886.00USD | - | 2026 Q1 |
| 3/5/2026 | -0.76USD | - | 1.03 MUSD | - | 2025 Q4 |
| 5/1/2024 | -0.47USD | - | 10.96 MUSD | - | 2024 Q1 |
| 2/29/2024 | -0.51USD | - | 9.43 MUSD | - | 2023 Q4 |
| 8/1/2023 | -0.75USD | - | 7.92 MUSD | - | 2023 Q2 |
| 5/2/2023 | -0.73USD | - | 7.41 MUSD | - | 2023 Q1 |
| 3/1/2023 | -0.63USD | - | 10.73 MUSD | - | 2022 Q4 |
| 11/2/2022 | -0.71USD | - | 10.80 MUSD | - | 2022 Q3 |
| 8/3/2022 | -0.53USD | - | 11.03 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the EyePoint stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
EyePoint shareholder structure
| % | Name |
|---|---|
14.73654% | |
14.68081% | |
12.74883% | |
10.07068% | |
8.96763% | |
6.39662% |
EyePoint Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
18.90% | SEC ↗ | |
16.60% | SEC ↗ | |
13.00% | SEC ↗ | |
12.36% | SEC ↗ | |
12.36% | SEC ↗ | |
12.36% | SEC ↗ | |
10.35% | SEC ↗ | |
10.35% | SEC ↗ | |
9.99% | SEC ↗ | |
9.99% | SEC ↗ |
EyePoint Executives and Management Board
12 members · avg. age 64 · 25 % women
Dr. Jay Duker (66)
President, Chief Executive Officer, Director · since 2016
5.95 M USD
Management
Mr. Ramiro Ribeiro (42)
Chief Medical Officer
Mr. George Elston (60)
Chief Financial Officer, Executive Vice President
Ms. Nancy Lurker (67)
Executive Vice Chairman of the Board · since 2016
Mr. Stern ..
Investor Relations · since 2022
Board of Directors
Dr. John Landis (72)
Non-Executive Independent Director
Dr. Goeran Ando (75)
Non-Executive Independent Chairman of the Board
Ms. Wendy Dicicco (57)
Non-Executive Independent Director
Ms. Karen Zaderej (63)
Non-Executive Independent Director
Mr. Stuart Duty (60)
Non-Executive Independent Director
Mr. Fred Hassan (79)
Non-Executive Independent Director
EyePoint Supply Chain
EyePoint Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.42 | 0.21 | 0.61 | ||
| 2 | -0.38 | 0.31 | 0.58 | ||
| 3 | 0.38 | -0.04 | 0.52 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.65 | -0.35 | — | ||
| 2 | 0.13 | -0.40 | -0.69 | ||
| 3 | 0.49 | -0.25 | -0.47 | ||
| 4 | 0 | -0.45 | 0.12 |
Frequently asked questions about EyePoint
EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.
EyePoint Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of EyePoint Pharmaceuticals Inc in the market are Aerie Pharmaceuticals Inc and Ocular Therapeutix Inc.
EyePoint Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative ophthalmic products. Founded in 1987, EyePoint has a rich history of advancing patient care in the field of ophthalmology. With a strong focus on sustained-release drug delivery systems, the company has successfully developed and received regulatory approvals for several cutting-edge ophthalmic treatments. EyePoint Pharmaceuticals Inc continues to thrive as a leading player in the industry, catering to the needs of patients worldwide. With its commitment to innovation and improving eye health, EyePoint Pharmaceuticals Inc has become a trusted name in the pharmaceutical sector.
EyePoint Pharmaceuticals Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative ophthalmic treatments, making a positive impact on patient care. EyePoint Pharmaceuticals Inc received FDA approval for its sustained-release intraocular implant, DEXYCU®, which is used for treating inflammation after cataract surgery. Additionally, the company gained FDA approval for YUTIQ®, a micro-insert used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. These milestones demonstrate EyePoint Pharmaceuticals Inc's commitment to advancing therapeutic options in the field of ophthalmology.
EyePoint Pharmaceuticals Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as Europe, specifically Germany, France, and the United Kingdom. Additionally, EyePoint Pharmaceuticals Inc has a presence in selected markets in Asia, including Japan. With its global reach, EyePoint Pharmaceuticals Inc aims to bring innovative ophthalmic products and therapies to patients worldwide.
EyePoint Pharmaceuticals Inc represents a strong commitment to improving patient outcomes through advanced ophthalmic therapeutic solutions. With a focus on innovation, the company is dedicated to developing and commercializing sustained-release drug delivery technologies. EyePoint Pharmaceuticals strives to address unmet medical needs and provide convenient treatment options to patients suffering from serious eye conditions. By leveraging its expertise and cutting-edge research, EyePoint Pharmaceuticals aims to enhance the quality of life for individuals worldwide.
Analysts currently set an average price target of 36.80 USD for the EyePoint stock (median: 33.66 USD), implying +717.9 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the EyePoint stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect EyePoint to generate revenue of 1.72 M USD and earnings per share of -2.52 USD.
Converted at the current exchange rate, the EyePoint share trades at 3.83 EUR (4.45 USD).
The EyePoint share (EYPT) is listed on 3 stock exchanges, including: NASDAQ (EYPT), Frankfurt (PV3B.F), München (PV3B.MU).
EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that develops and markets innovative drugs for body tissues and eye diseases. The company's business model focuses on the development, manufacturing, and marketing of therapeutics for chronic eye diseases such as macular degeneration, diabetic retinopathy, and uveitis. EyePoint Pharmaceuticals specializes in strategic partnerships and collaborations with renowned pharmaceutical companies and global organizations. The company offers drug solutions such as Iluvien, used for the treatment of macular degeneration, and Yutiq, intended for chronic uveitis therapy. Iluvien is a steroid implant composed of a unique formulation of fluocinolone acetonide (FAc) and a biopolymer that slowly degrades during use. It has a unique ability to exert a sustained effect on eye disease, significantly reducing the need for repeated intravitreal injections. Iluvien is approved in Europe and Canada and has been submitted to the US Food and Drug Administration (FDA). Yutiq is a steroid implant developed for the treatment of chronic uveitis. It is implanted into the posterior chamber of the eye and releases the active ingredient triamcinolone acetonide (TAc) to reduce inflammation. Yutiq has been approved by the FDA and is currently available in the United States. In addition, EyePoint Pharmaceuticals also offers Dexpel, a technology platform for long-lasting surgical implants. This platform can be utilized in various medical fields such as oncology, orthopedics, and neurosurgery to control drug release, prolong treatment duration, and reduce the need for repeated injections. EyePoint Pharmaceuticals also pursues a diversification strategy to expand its product portfolio and create stable growth. This includes collaborating with other companies to provide technology solutions and services tailored to the needs of customers. Overall, the business model of EyePoint Pharmaceuticals aims to bring innovative drugs to the market that enable effective treatment of eye diseases and significantly improve patients' quality of life. The company relies on a combination of well-established and innovative technologies to control drug release and ensure optimal therapy.
The expected revenue of EyePoint is 1.72 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of EyePoint is -209.57 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of EyePoint is currently -1.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the EyePoint stock.
The price-to-sales ratio (P/S) of EyePoint is currently 214.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the EyePoint stock.
The Eulerpool Quality Score for EyePoint is 2/10.
The ISIN of EyePoint is US30233G2093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of EyePoint is A2QJRU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of EyePoint is EYPT. The ticker symbol is used to trade EyePoint shares on the stock exchange.
EyePoint paid dividends every year for the past 0 years.
EyePoint is assigned to the 'Health' sector.
The dividends of EyePoint are distributed in USD.
EyePoint stock
EyePoint Peer Group
EyePoint Ticker
EyePoint FIGI
All fundamentals and in-depth analysis of EyePoint
Our stock analysis for EyePoint stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.